Biomea Fusion Announces Proposed Public Offering of Securities

SAN CARLOS, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, announced today that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, Biomea intends to grant the underwriter a 30-day option to purchase up to an additional fifteen percent (15%) of the total number of shares of common stock and pre-funded warrants in the proposed offering. All of the shares of common stock and pre-funded warrants to be sold in the proposed offering are to be sold by Biomea.